VenowaveWhile most (if not ALL) investors wait on the FDA EUA for AcuVid, Imho, the elephant in the room for Therma Bright is Venowave. The following video provides an indication of the work that went into and the significant potential expressed in its indications as a therapeutic tool. There were scientific papers written at the time that represent the scrutiny that went into its efficacy as a therapeutic tool post surgery and for DVT prevention.
https://youtu.be/OEVj0YiH7oI Another piece of the puzzle is that the purchase price for the rights to it (a little over two years ago) was cheap. At the time it wasn't even considered the feature technology.
- Sale price - $500,000 with a minimum of 10% payable in cash and the balance in shares of Therma Bright Inc.
- Products include Benepod® for chronic pain, ICEOtherm® for minor aches and pain in the hands, elbows and feet, and Venowave® to increase circulation.
The original device was plagued with quality control issues and I expect that John Saringer didn't have the connections or pockets deep enough to change this reality. After all he was an inventor, not a business man.
If it is demonstrated that Rob can turn this $500,000 purchase into something amounting to
$10 million + annually the positive returns for longterm investors could be extraordinary. While it may currently be a BIG if, he would then have the capital to modify the AcuVid technology to test for multiple diseases and infections.
GLTE!!!